- Home
- PAVM vs BRTX Comparison
PAVM vs BRTX Comparison
Compare PAVM & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVM
- BRTX
- Stock Information
- Founded
- PAVM 2014
- BRTX 1997
- Country
- PAVM United States
- BRTX United States
- Employees
- PAVM N/A
- BRTX N/A
- Industry
- PAVM Medical/Dental Instruments
- BRTX Managed Health Care
- Sector
- PAVM Health Care
- BRTX Health Care
- Exchange
- PAVM Nasdaq
- BRTX Nasdaq
- Market Cap
- PAVM 12.0M
- BRTX 12.6M
- IPO Year
- PAVM 2016
- BRTX N/A
- Fundamental
- Price
- PAVM $0.59
- BRTX $1.60
- Analyst Decision
- PAVM Strong Buy
- BRTX Strong Buy
- Analyst Count
- PAVM 1
- BRTX 1
- Target Price
- PAVM $19.00
- BRTX $18.00
- AVG Volume (30 Days)
- PAVM 135.9K
- BRTX 152.5K
- Earning Date
- PAVM 08-11-2025
- BRTX 08-12-2025
- Dividend Yield
- PAVM N/A
- BRTX N/A
- EPS Growth
- PAVM N/A
- BRTX N/A
- EPS
- PAVM 0.96
- BRTX N/A
- Revenue
- PAVM $1,993,000.00
- BRTX $391,000.00
- Revenue This Year
- PAVM N/A
- BRTX $391.52
- Revenue Next Year
- PAVM $455.63
- BRTX $3.50
- P/E Ratio
- PAVM $0.62
- BRTX N/A
- Revenue Growth
- PAVM N/A
- BRTX 161.54
- 52 Week Low
- PAVM $0.54
- BRTX $1.21
- 52 Week High
- PAVM $1.90
- BRTX $2.55
- Technical
- Relative Strength Index (RSI)
- PAVM 45.52
- BRTX 45.93
- Support Level
- PAVM $0.54
- BRTX $1.51
- Resistance Level
- PAVM $0.61
- BRTX $1.79
- Average True Range (ATR)
- PAVM 0.03
- BRTX 0.10
- MACD
- PAVM 0.00
- BRTX -0.00
- Stochastic Oscillator
- PAVM 54.54
- BRTX 32.14
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.